68th annual meeting of the American Academy of Dermatology: Miami Beach, Florida, USA, 59 March 2010

American Journal of Clinical Dermatology

Volumn 11, Issue 3, 2010, Pages 223-224

  Fraser, Kathy ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Acetylcysteine; Adverse reactions; Alpha adrenergic receptor agonists; BG 12; Briakinumab; Brimonidine; Contact dermatitis; Therapeutic use

Indexed keywords

ABT 874; ACETYLCYSTEINE; BRIMONIDINE; CLOMIPRAMINE; ETANERCEPT; INTERLEUKIN 12; OXYMETAZOLINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ALOPECIA; BONE DISEASE; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTACT DERMATITIS; DERMATOLOGY; DRUG EFFICACY; HUMAN; LYMPHOMA; MEDICAL SOCIETY; MELANOMA; PRIORITY JOURNAL; PSORIASIS; ROSACEA; SKIN DISEASE; TRICHOTILLOMANIA; VITAMIN D DEFICIENCY;

DERMATOLOGIC AGENTS; DERMATOLOGY; HUMANS; SKIN DISEASES; SOCIETIES, MEDICAL; UNITED STATES;

EID: 77950645437     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11533270-000000000-00000     Document Type: Conference Paper

References (9)

1. Leonardi CL, Kimball AB, Papp KA, et al., for the PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371 (9625): 1655-1674
2. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371 (9625): 1675-1684
3. Griffiths CE, Strober BE, van de Kerkhof P, et al., ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362 (2): 118-128
4. Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treatedwith anti- TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010 Feb; 69 (2): 400-408
5. Dharamsi JW, Bhosle M, Balkrishnan R, et al. Using 'number needed to treat' to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-alpha inhibitors for patients with severe psoriasis. Br J Dermatol 2009 Sep; 161 (3): 605-616
6. Williams JD, Coulson IH, Susitaival P, et al. An outbreak of furniture dermatitis in the UK. Br J Dermatol 2008; 159 (1): 233-234
7. American Academy of Dermatology and AAD Association. Position statement on vitamin D, issued 11/08 [online]. Available from URL: http://www. aad.org/Forms/Policies/Uploads/PS/PS-Vitamin%20D.pdf [Accessed 2010 Mar 17]
8. Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2009 Jul; 66 (7): 756-763
9. Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol 2007 Nov; 143 (11): 1369-1371